Form 4: Foghorn Therapeutics CBO Granted 165,000 Stock Options

Foghorn Therapeutics' Chief Business Officer, Anna Rivkin, was granted 165,000 stock options with an exercise price of $5.71 per share.

Summary

• Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc. (FHTX), was granted 165,000 stock options.
• The options have an exercise price of $5.71 per share.
• The grant date for these options was January 30, 2026.
• The options vest as to 25% of the underlying shares on January 30, 2027, and then 6.25% on the first day of each calendar quarter thereafter.
• The options expire on January 29, 2036.
• Following this transaction, Anna Rivkin beneficially owns 165,000 derivative securities.
• A Limited Power of Attorney was granted by Anna Rivkin on December 1, 2025, to Michael LaCascia, Adrian Gottschalk, and Samantha Macina to handle her SEC filings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational changes or financial performance.

Positives

• The grant of stock options aligns the Chief Business Officer's interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $5.71 per share indicates a baseline value for future stock appreciation.

Risks

• The value of the stock options is contingent on the future market price of Foghorn Therapeutics Inc. common stock exceeding the exercise price of $5.71.
• If the company's stock price does not appreciate above the exercise price, the options may expire worthless.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports an executive compensation event.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like a Chief Business Officer is a common practice in the biotechnology industry, aiming to attract, retain, and motivate talent by aligning their financial incentives with long-term shareholder value creation. This is particularly relevant in biotech where long development cycles require sustained executive commitment.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a standard practice across industries, including biotechnology, comparable to companies like Moderna or BioNTech, which frequently use equity incentives to reward and retain key personnel.
• The vesting schedule, typically over several years (e.g., 4 years with a one-year cliff), is also a common structure designed to encourage long-term commitment and performance, similar to equity grants observed at peer biotech firms.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, ensuring that the executive benefits only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The options will begin to vest on January 30, 2027, with subsequent quarterly vesting.
• Anna Rivkin may exercise these options at any time after they vest and before their expiration date of January 29, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not provide new information that would fundamentally alter the investment thesis for Foghorn Therapeutics. It reinforces management's alignment with long-term shareholder value but offers no immediate catalysts for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Foghorn Therapeutics, FHTX, Anna Rivkin, Stock Options, Insider Trading, SEC Form 4, Executive Compensation, Derivative Securities, Biotechnology